Home / Intelligence / Webinars / How to Position Evidence for Successful Commercialization
Available On Demand
| The HEOR Evidence Generation team at Trinity Life Sciences will conduct a webinar to discuss recent publications geared towards crafting the value story for products prior to launch. Please join us to learn what evidence is needed and how best to position it for successful commercialization. We will present original work conducted on behalf of our valued clients in several different therapeutic areas – Oncology, Cardiology, and Rare Genetic Disorders. |
| You already know the importance of driving awareness and conducting market shaping activities as you launch a new product. But what steps do you specifically need to take? How would you characterize the market today, and articulate the unmet need for your product? Come learn with the Trinity Evidence Generation team! |
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
Related Intelligence
White Papers
Measuring the Impact of Field Medical Affairs
Demonstrating the value of Field Medical Affairs has, to date, been a challenge due to its qualitative and non-promotional nature. Traditional, activity-based metrics have missed the mark on translating Field Medical Affairs activities to tangible milestones, such as changes in HCP perception, HCP advocacy or closing critical care gaps that impact overall patient outcomes. When […]
Read More
White Papers
Evidence Generation in a Post-IRA World
Since the passage of the Inflation Reduction Act (IRA) in 2022, the pharmaceutical industry has significantly altered how they approach and plan for evidence generation activities to best support product launches and pricing and access negotiations. Leading life science companies are taking proactive steps to adjust how and when they develop evidence and how they […]
Read More
White Papers
Annual State of Global Market Access
In 2023, the life sciences industry saw key therapeutic advances in sickle cell disease, obesity/weight management, and Duchenne muscular dystrophy, among others, and the continued approvals of therapies with cutting edge mechanisms, including the first CRISPR therapy. While 2022 was characterized by accelerated development processes and the rapid evolution of therapeutic standards, 2023 featured increased […]
Read More